Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 94

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 94
---
 Time represented shares of Common Stock (an “Old Certificate”) shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.” FIFTH: This amendment to the Corporation’s Amended and Restated Certificate of Incorporation was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware and shall be effective on and as of the date of filing of this Certificate of Amendment with the Secretary of State of the State of Delaware. *************************************** A-1

TABLE OF CONTENTS

IN WITNESS WHEREOF, Plus Therapeutics, Inc. has caused this Certificate of Amendment to be signed by the undersigned, thereunto duly appointed, this [] day of [], [].

| PLUS THERAPEUTICS, INC. |     |                                       |
| By:                     |     |                                       |
| Name:                   |     | Marc H. Hedrick, M.D                  |
| Title:                  |     | President and Chief Executive Officer |

A-2

TABLE OF CONTENTS Appendix B PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN SECTION 1 ESTABLISHMENT AND PURPOSE. (a) The Plan was adopted by the Board of Directors on April 30, 2020 and approved by the Company’s stockholders on June 16, 2020. The Plan was amended and restated by the Board of Directors on March 22, 2021, subject to approval of the Company’s stockholders, which approval occurred on May 17, 2021. The Plan was further amended and restated by the Board of Directors on March 28, 2022, subject to approval of the Company’s stockholders, which approval was obtained on May 16, 2022. The Plan was further amended and restated by the Board of Directors on February 24, 2023, subject to approval of the Company’s stockholders, which approval was obtained on April 20, 2023. The Plan was further amended and restated by the Board of Directors on July 8, 2024, subject to approval of the Company’s stockholders, which approval was obtained on August 15, 2024. The Plan was further amended and restated by the Board of Directors on July [•], 2025, subject to approval of the Company’s stockholders. The Plan was initially